UNSPSC 51112403: Dacarbazine citrate

This classification denotes a triazene compound with the molecular formula C6H10N6O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9UYU348NIF. European Medicines Agency schedules dacarbazine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01547MIG. As of Q4 2014, DACARBAZINE CITRATE remains US FDA's Preferred Term for this commodity. Most nations, for tariff and trade purposes, schedule dacarbazine citrate under HS 29332990 and SITC 51573.

SMILES: CN(C)/N=N/C1C(NC[NH]1)C(=O)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51112403 Dacarbazine citrate is a Commodity code covering procurement of this chemotherapy agent by state and local health systems, departments, and purchasing cooperatives. State and local governments purchase dacarbazine citrate primarily through health department pharmaceutical procurement channels, hospital group purchasing organizations, and state Medicaid programs to support oncology treatment protocols in public health facilities and safety-net hospitals. The drug is commonly acquired via competitive bidding on state pharmaceutical contracts, often bundled within broader oncology or IV-infusion drug schedules rather than as a standalone item.

The source contains no recent state or local solicitation records tagged to this code. Without posted opportunities in the recent-opportunities block, the current procurement activity under UNSPSC 51112403 cannot be characterized by issuing body, geographic concentration, or representative solicitations. Dacarbazine citrate procurement by state and local entities typically follows established pharmaceutical contracting cycles through state health departments and cooperative purchasing programs, but no current RFP, RFQ, IFB, or ITB records support decision-relevant timing or issuing-body detail at this time.